TACSTD2 and cancer: In androgen-independent prostate cancer cells however, TROP2 does not appear to mark cells with enhanced treatment resistance ability but rather enriches cell sub-populations with high self-renewal potential, which represent a characteristic of cancer stem cells and progenitor cells.